How to test a stock after an equity raise

September 24, 2026 · 8 min readnews-to-thesisequity-issuancedilution

Companies are selling more stock, and the useful question isn't whether an equity raise is good or bad. Start with what the cash lets the company do. Then measure how much ownership each existing share gave up and ask whether operating traction makes this raise a bridge instead of a habit. That turns a financing headline into a testable thesis.

The SEC's market update published on September 23 counted 557 follow-on registered offerings raising more than $111 billion in the first half of 2026. The comparable period had 505 offerings raising nearly $84 billion. The same release counted 208 initial public offerings raising more than $137 billion, versus 180 raising more than $27 billion. Capital raising is open again. That doesn't tell you which issuers used the opening well.

Why doesn't an equity raise deserve one verdict?

A follow-on offering is a registered sale of shares by a company that is already public. When the company sells newly issued shares, cash enters the business and the ownership represented by each old share shrinks. That's dilution. When existing holders sell their own shares, the company may receive none of the proceeds. The prospectus tells you which transaction you're looking at.

The same arithmetic can fund very different businesses. A company might build capacity against visible demand or plug a recurring cash deficit. It might also sell stock after a price run because equity is its cheapest available financing. Calling every raise bullish ignores dilution. Calling every raise bearish ignores the asset or runway bought with the proceeds.

The aggregate numbers need the same care. The SEC reported that first-half IPO proceeds rose nearly 400% while the count rose about 16%. A few large transactions can move dollars much more than deal count. Renaissance Capital's third-quarter review published on September 24 makes the concentration plain: it reported 31 listings and $34.9 billion raised, with $26.5 billion tied to one US offering by Korea-listed SK hynix. That review appeared before the calendar quarter ended, and its taxonomy differs from the SEC's. Use both as evidence that the issuance window is active. Don't splice their totals into one series.

What does the filing say about the new shares?

Start with the prospectus, then move to the financial statements. A filing-driven review asks five blunt questions.

Who is selling? Primary shares bring cash to the issuer. Secondary shares transfer ownership between investors. A mixed deal does both. A headline offering size doesn't answer how much capital reached the company.

What is the dilution? Compare the new shares with the pre-offering share count. Then read the filing's dilution section, which usually presents the gap between the offer price and tangible book value per share after the transaction. These are different lenses. Share-count dilution measures ownership. Book-value dilution compares price paid with accounting net assets allocated to the new share.

Where will the cash go? “General corporate purposes” leaves more work than a named project. Debt repayment can lower interest expense without growing revenue. An acquisition can add revenue while destroying return on capital. A new plant can depress free cash flow before it contributes output. Write down the promised use because that's the claim later filings have to grade.

Did the business earn the right to raise? Revenue growth and positive operating cash flow don't guarantee good deployment. They do distinguish an operating business with financing options from one whose model still depends on fresh equity to keep the lights on.

Has this happened before? One raise can finance a step change. Repeated issuance alongside persistent cash burn is a financing loop. Share count and dilution explains why the cash-flow statement's issuance line and the income statement's weighted-average shares answer different parts of this question.

How can filed fundamentals test the raise?

A market-wide first pass can't read every prospectus sentence. It can look for the financial footprint around a completed issuance.

Use stock_issued, the cash proceeds reported in the financing section of the cash-flow statement, to identify companies that recently raised equity. Scale it by market capitalization so the same cash amount doesn't look equally important for companies of very different size. Then separate the latest trailing window from the preceding one. The second window asks whether issuance is an event or a recurring source of cash.

Pair that with three operating checks:

Revenue is growing over a comparable period.
Operating cash flow is positive relative to revenue.
Free cash flow shows whether capital spending still absorbs more cash than operations produce.

The last check needs interpretation. Negative free cash flow after a raise can be exactly what management promised if proceeds are funding a buildout. It can also show that the core operation still can't finance itself. Arithmetic raises the question; the use-of-proceeds disclosure tells you which claim to test next.

This structure builds on operating cash flow versus net income. Reported profit can rise while the business consumes cash, so earnings alone are a weak judge of whether new equity bought real operating progress.

How would you write the equity-raise thesis?

The shape below is illustrative, and the bundled templates plus the Quantery DSL reference are the reference for exact supported fields. The thresholds are proposed research parameters. Change them and re-run.

meta:
  name: equity-raise-with-traction
  label: Equity Raise With Traction
  description: Recent equity proceeds backed by operating progress.
  scale: { min: 0, max: 2 }

universe:
  exchanges: [NYSE, NASDAQ, AMEX]
  min_market_cap: 200000000
  exclude_sectors: [Financial Services, Real Estate]

quality:
  stale_months: 9
  required:
    price: no_price
    market_cap: no_market_cap
    revenue_ttm: no_revenue
    ocf_ttm: no_operating_cash_flow

params:
  raise_large:           0.10
  raise_present:         0.03
  prior_raise_low:       0.02
  prior_raise_max:       0.05
  revenue_growth_strong: 0.10
  ocf_margin_strong:     0.05

features:
  issuance_ttm:      coalesce(ttm(stock_issued), 0)
  issuance_8q:       coalesce(sum(stock_issued, 8), 0)
  prior_issuance:    issuance_8q - issuance_ttm
  revenue_ttm:       ttm(revenue)
  ocf_ttm:           ttm(operating_cash_flow)
  fcf_ttm:           ttm(free_cash_flow)
  raise_load:        if(market_cap > 0, issuance_ttm / market_cap, null)
  prior_raise_load:  if(market_cap > 0, prior_issuance / market_cap, null)
  revenue_growth:    cagr(revenue, 4)
  ocf_margin:        if(revenue_ttm > 0, ocf_ttm / revenue_ttm, null)
  fcf_margin:        if(revenue_ttm > 0, fcf_ttm / revenue_ttm, null)

criteria:
  history:
    rules:
      - { when: "history_periods >= 8", score: 1 }
      - { when: "history_periods < 8", score: 0, flag: insufficient_history }
      - { else: 0 }
  capital_event:
    rules:
      - { when: "is_null(raise_load) or issuance_ttm <= 0", score: 0, flag: no_equity_raise }
      - { when: "raise_load >= $raise_large", score: 2 }
      - { when: "raise_load >= $raise_present", score: 1 }
      - { else: 0 }
  operating_progress:
    rules:
      - { when: "is_null(revenue_growth) or is_null(ocf_margin)", score: 0, flag: no_operating_comparison }
      - { when: "revenue_growth >= $revenue_growth_strong and ocf_margin >= $ocf_margin_strong", score: 2 }
      - { when: "revenue_growth > 0 and ocf_ttm > 0", score: 1 }
      - { else: 0 }
  financing_pattern:
    rules:
      - { when: "is_null(prior_raise_load)", score: 0, flag: no_prior_window }
      - { when: "prior_raise_load <= $prior_raise_low", score: 2 }
      - { when: "prior_raise_load <= $prior_raise_max", score: 1 }
      - { when: "prior_raise_load > $prior_raise_max", score: 0, flag: repeated_issuance }
      - { else: 0 }
  cash_result:
    rules:
      - { when: "is_null(fcf_margin)", score: 0, flag: no_fcf_margin }
      - { when: "fcf_margin >= 0", score: 2 }
      - { when: "ocf_margin > 0", score: 1 }
      - { else: 0 }

gate:
  mode: strict

The structure makes several choices visible. raise_load compares trailing issuance proceeds with today's market capitalization. That's a rough measure of financing significance, not the actual percentage dilution. Offer price and issuance date can break that shortcut. So can employee grants, conversions, or a large price move. Confirm the share count and transaction terms in the filing before treating a qualifying company as a completed raise of the proposed size.

The two issuance windows don't overlap. issuance_8q - issuance_ttm removes the recent trailing amount and leaves the preceding filing positions. The history rule demands enough observations for that comparison. It still won't distinguish common shares from every other item a provider may map into stock issuance, or primary proceeds from secondary shares that never touched company cash. Those are filing checks.

The gate is strict because the question is narrow: recent capital, enough history, operating progress, no heavy earlier issuance, and a cash result that can be interpreted. If you want to study cash-burning buildouts, loosen cash_result into a score instead. Don't let a different hypothesis sneak through a convenient threshold.

What should the backtest compare?

Run the thesis walk-forward on point-in-time filings, with a reporting lag so issuance cash isn't visible before the filing becomes public. Every result is hypothetical and excludes costs. The first comparison is against the same rules with financing_pattern removed. That isolates whether avoiding repeated raisers helped, or whether revenue growth and cash generation did all the work.

Then split the events into groups the numeric thesis can't settle by itself:

Primary offerings versus deals dominated by selling holders.
Debt repayment versus expansion or acquisition uses.
Positive free cash flow versus cash-consuming investment.
First issuance in the observed window versus repeated issuance.

Record those labels from the contemporaneous prospectus before looking at later returns. Otherwise “productive use” becomes a story assigned after the stock worked. How to turn a filing into a testable thesis covers that fact-to-proxy handoff in detail.

Re-test nearby round thresholds. Compare holding periods long enough for the promised use of cash to reach a filing. Check sectors separately because equity financing means something different for a clinical-stage biotech than for an established manufacturer. Watch coverage: a company that just became public may lack the filing history this version requires, so the thesis studies follow-on issuers with an operating record more readily than fresh IPOs.

A passing result would show that this combination of issuance pattern and filed operating traits was associated with different subsequent outcomes in the sample tested. It wouldn't prove that raising equity created the outcome. Companies choose when to issue, and favorable markets, strong prices, or urgent financing needs affect that choice.

The issuance boom gives you companies to study. Write down each prospectus promise, then grade it against later filings. An offering headline is now a rule you can change and test again.

Research tooling, not investment advice. Nothing here is a recommendation to buy, sell, or hold any security. Screens, scores, and backtests are informational only; backtested results are hypothetical, exclude costs such as commissions and slippage, and do not guarantee future results. Verify against primary filings and make your own decisions.

Want to try this on your own rules? Quantery is free for 14 days: the full app, no card required.

← All articles